BioCrossroads is investing $300,000 in Indianapolis-based biotechnology start-up AgeneBio which is focused on the development of therapeutic products for Alzheimer's disease, dementia and other memory disorders. Tim Parshall, CEO, AgeneBio has details.
Keywords: Indiana Seed Fund, BioCrossroads, AgeneBio, Alzheimer's disease, dementia, Tim Parshall
